ICAN
LIVE

Add to watchlist:

No watchlists yet
View on USPTO

ICAN Trademark

Serial Number: 87003192 • Registration: 5383250

ICAN is a trademark filed by International Cancer Advocacy Network on April 15, 2016. The trademark is classified under Class 36 (Insurance & Financial), Class 41 (Education & Entertainment), Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 45 (Legal & Security Services), Class 35 (Advertising & Business). The application is currently registered and active.

Owner Contact Info

International Cancer Advocacy Network (6 trademarks)

Phoenix, AZ 850217246

Entity Type: 99

Trademark Details

Filing Date

April 15, 2016

Registration Date

January 23, 2018

Published for Opposition

November 7, 2017

Goods & Services

Co-sponsoring and providing educational conferences, both live and via telephone conferences, seminars, classes and workshops in the field of cancer-related issues and distribution of educational materials in connection therewith; on-line journals, namely, blogs featuring information in the field of cancer-related issues; providing podcasts and non-downloadable videos in the field of cancer-related issues; providing on-line journals, namely, blogs featuring cancer-related issues and postings in honor of patients and in memory of patients

Charitable fundraising to support providing educational services and information about prevention, screening, diagnosis and treatment of cancer, cancer patient navigation services, cancer patient and clinical trials advocacy programs, research, development and regulatory approval of methods, drugs and devices for prevention, screening, diagnosis and treatment of cancer, lobbying and legislation regarding cancer-related issues, patient-provider communications, and patient-payor communications; providing information concerning the patient's financial reimbursement from medical insurers and patient assistance programs in the nature of cost-mitigating health reimbursement arrangements for cancer treatment; providing information regarding insurance coverage and patient assistance programs in the nature of cost-mitigating health reimbursement arrangements for cancer patients for diagnostic tests, drugs and medical devices

Lobbying services, namely, promoting the interests of cancer patients, cancer researchers, cancer treatment providers, and others involved with cancer research, diagnosis and treatment; providing information in the field of patient-payor communications in which information regarding medical billing can be exchanged; providing information in the field of government affairs related to the expanded access to experimental cancer drugs for compassionate use; providing physician and medical specialist referrals to patients fighting chronic diseases and lethal diseases for assisting in the access to second opinions; providing information in the nature of discounts and rebates for cancer patients for diagnostic tests, drugs and medical devices

Providing patient advocacy and patient advocate services in the field of cancer treatment; providing cancer patient advocacy programs; providing advocacy services to potential participants and participants in clinical trials; providing information in the field of personal emotional support of cancer patients and patients' families; providing information in the field of regulatory affairs compliance relating to the approval of anticancer compounds in the U.S. and abroad

Providing information about prevention, screening, diagnosis and treatment of cancer; providing a website, and links to the websites of others, featuring information about prevention, screening, diagnosis and treatment of cancer; providing information in the field of patient medical information where patients can inquire about medical issues and be directed to resources for medical information customized to their need for information about their condition; providing information in the field of cancer prevention, screening, diagnosis and treatment; providing information in the field of cancer treatment for the benefit of patients and patients' families; providing information in the field of communications between patients and health care providers in which patient medical information can be exchanged; providing information in the field of patient access to diagnostic tests, drugs and medical devices provided by health care facilities; providing information in the field of medicine, personalized medicine, pathology, oncology, interventional radiology, radiogenomics, and anesthesiology; providing information in the field of complementary and alternative medicine for use in the prevention and treatment of cancer; providing access to medical specialists for second opinions for patients fighting chronic diseases and lethal diseases

Providing information in the field of anti-cancer drug discovery and development; providing information in the field of clinical trials

Filing History

NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
Jul 27, 2024 NA85
REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
Jul 27, 2024 C15A
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Jul 27, 2024 APRE
TEAS SECTION 8 & 15 RECEIVED
Jan 12, 2024 E815
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Jan 23, 2023 REM1
REGISTERED-PRINCIPAL REGISTER
Jan 23, 2018 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Nov 7, 2017 NPUB
PUBLISHED FOR OPPOSITION
Nov 7, 2017 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Oct 18, 2017 NONP
ASSIGNED TO LIE
Oct 1, 2017 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Sep 16, 2017 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 8, 2017 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 7, 2017 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Sep 7, 2017 ERFR
NOTIFICATION OF FINAL REFUSAL EMAILED
Mar 19, 2017 GNFN
FINAL REFUSAL E-MAILED
Mar 19, 2017 GNFR
FINAL REFUSAL WRITTEN
Mar 19, 2017 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 3, 2017 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 2, 2017 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Feb 2, 2017 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Aug 3, 2016 GNRN
NON-FINAL ACTION E-MAILED
Aug 3, 2016 GNRT
NON-FINAL ACTION WRITTEN
Aug 3, 2016 CNRT
ASSIGNED TO EXAMINER
Jul 29, 2016 DOCK
NOTICE OF PSEUDO MARK E-MAILED
Apr 21, 2016 MPMK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 20, 2016 NWOS
NEW APPLICATION ENTERED
Apr 19, 2016 NWAP